8GF9
Cryo-EM structure of human TRPV1 in cNW11 nanodisc and POPC:POPE:POPG lipids
Summary for 8GF9
| Entry DOI | 10.2210/pdb8gf9/pdb |
| Related | 8GF8 8GFA |
| EMDB information | 29981 29982 29983 |
| Descriptor | Transient receptor potential cation channel subfamily V member 1, (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate, (2R)-3-{[(R)-hydroxy{[(1S,2R,3R,4S,5S,6R)-2,3,4,5,6-pentahydroxycyclohexyl]oxy}phosphoryl]oxy}propane-1,2-diyl dioctadecanoate, ... (5 entities in total) |
| Functional Keywords | transient receptor potential v family member 1, trp, apo, human, channel, trpv1, trp channels, pain, membrane protein, cnw11, nanodiscs, thermo-trp, temperature sensation, vanilloid, popc:pope:popg |
| Biological source | Homo sapiens (human) |
| Total number of polymer chains | 4 |
| Total formula weight | 529178.39 |
| Authors | Neuberger, A.,Nadezhdin, K.D.,Sobolevsky, A.I. (deposition date: 2023-03-07, release date: 2023-05-10, Last modification date: 2024-10-09) |
| Primary citation | Neuberger, A.,Oda, M.,Nikolaev, Y.A.,Nadezhdin, K.D.,Gracheva, E.O.,Bagriantsev, S.N.,Sobolevsky, A.I. Human TRPV1 structure and inhibition by the analgesic SB-366791. Nat Commun, 14:2451-2451, 2023 Cited by PubMed Abstract: Pain therapy has remained conceptually stagnant since the opioid crisis, which highlighted the dangers of treating pain with opioids. An alternative addiction-free strategy to conventional painkiller-based treatment is targeting receptors at the origin of the pain pathway, such as transient receptor potential (TRP) ion channels. Thus, a founding member of the vanilloid subfamily of TRP channels, TRPV1, represents one of the most sought-after pain therapy targets. The need for selective TRPV1 inhibitors extends beyond pain treatment, to other diseases associated with this channel, including psychiatric disorders. Here we report the cryo-electron microscopy structures of human TRPV1 in the apo state and in complex with the TRPV1-specific nanomolar-affinity analgesic antagonist SB-366791. SB-366791 binds to the vanilloid site and acts as an allosteric hTRPV1 inhibitor. SB-366791 binding site is supported by mutagenesis combined with electrophysiological recordings and can be further explored to design new drugs targeting TRPV1 in disease conditions. PubMed: 37117175DOI: 10.1038/s41467-023-38162-9 PDB entries with the same primary citation |
| Experimental method | ELECTRON MICROSCOPY (2.58 Å) |
Structure validation
Download full validation report
